Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Centessa Pharmaceuticals plcNASDAQ: CNTA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $30.47M rose 887.3% year over year, ahead of the -10.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 89.2% from the prior quarter. Over 3 fiscal years it compounded at +760.8% a year.

Context

  • Financing cash flow amounted to 1943.5% of revenue in FY2025.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +887.3% holds above the trailing-twelve-month pace of -10.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$30.47M-89.2% QoQ
Last fiscal yearDec 2025
$291.53M-20.1% YoY
LTMMar 2026
$318.91M-10.8% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+887.3%——
1 year-20.1%——
3-year CAGR+760.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
291.53M USD
Year-over-year change
-20.1%
4-year CAGR
-18.5%

Financing Cash Flow vs competitors

How CNTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.8% is the 9th highest of 10, against a peer median of +707.0%.
  • Over three fiscal years its annual growth of +760.8% compares with a peer median of +33.1%.
CNTA Competitors
Financing Cash Flow for CNTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥2.54B CNY+707.0%+60.1%454.8%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$956.8M USD+5992.0%-25.1%—
APGEApogee Therapeutics, Inc.LTM Jun 2026$912.87M USD+1861.4%+33.1%—
CELCCelcuity Inc.LTM Jun 2026$777.67M USD+11487.0%+44.2%—
DYNDyne Therapeutics, Inc.LTM Jun 2026$713.47M USD+170.6%+187.7%—
CGONCG Oncology, Inc. Common stockLTM Sep 2026$504.27M USD+81.4%+8.7%8178.2%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$477.84M USD+19.6%-1.6%71.4%
CNTACentessa Pharmaceuticals plcLTM Mar 2026$318.91M USD-10.8%+760.8%—
LEGNLegend Biotech CorporationLTM Sep 2026$115.15M USD+822385.3%—8.5%
ZLABZai Lab LimitedLTM Jun 2026$44.64M USD-86.6%—9.9%
Peer median (excluding CNTA) —+707.0%+33.1%71.4%

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(381.85M)(216.21M)(151.09M)(235.76M)(197.53M)
Depreciation & Amortization34K131K810K942K921K
Deferred Income Tax0(2.86M)(26.53M)2.65M2.51M
Stock-Based Compensation024.97M29.39M33.55M30.96M
Change in Working Capital(5.38M)(2.83M)(18.86M)22.1M(51.24M)
Accounts Receivables(6.72M)(11.71M)(12.09M)(6.6M)2.91M
Inventory00000
Accounts Payables06.35M(2.72M)(4.59M)2.96M
Other Working Capital1.34M2.53M(4.04M)33.29M(57.11M)
Other Non-Cash Items251.06M(3.75M)5.93M34.46M20.56M
Operating Cash Flow(136.14M)(200.55M)(160.34M)(142.06M)(193.82M)
Capital Expenditures(185.98K)(1.14M)(169K)(34K)(371K)
Acquisitions (Net)63.43M0000
Purchases of Investments00(264.91M)(140.53M)(739.76M)
Sales of Investments00138.08M171.83M321.6M
Other Investing Activities0206K000
Investing Cash Flow63.25M(931K)(127M)31.27M(418.53M)
Debt Repayment73.64M00(762K)0
Common Stock Issued586.44M718K20.81M359.61M296.72M
Common Stock Repurchased(12K)0000
Dividends Paid00000
Other Financing Activities0(261K)310K5.91M(5.19M)
Financing Cash Flow660.07M457K21.12M364.75M291.53M
Effect of Forex Changes2.9M(418K)615K1.23M(448K)
Net Change in Cash590.08M(201.44M)(265.61M)255.19M(321.27M)
Free Cash Flow(136.33M)(201.68M)(160.51M)(142.09M)(194.19M)

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.